Hydroxychloroquine for the management of recalcitrant oral lichen planus
Copyright © 2023 Elsevier Inc. All rights reserved..
OBJECTIVE: The objective of this study is to describe the efficacy of hydroxychloroquine (HCQ) in patients with oral lichen planus (OLP) refractory to conventional therapy.
STUDY DESIGN: In this single-center retrospective study, patients were prescribed HCQ 200 mg twice daily. Pain, reticulation, erythema, and ulceration scores were recorded. Two-sample and paired t tests were used to evaluate mean and paired pain scores and paired t test to determine substantial differences in paired REU scores, at HCQ initiation visit and final follow-up at 12 to 24 months.
RESULTS: Thirty-six patients (69.4% female) with a median age of 70 ± 12.0 (range 48-99) were initiated on HCQ. Only 30 patients were evaluable because pruritus developed in 5 patients (13.9%) and gastrointestinal symptoms in 1 (2.8%). The mean follow-up was 23.2 months (range 1-74). In 19 patients, there was a significant decline in the worst pain score from a mean of 3.9 (SD± 2.8, n = 19) to 1.9 (SD ± 2.4, n = 19) (t = 2.837, P < .006). Paired reticulation, erythema, and ulceration (REU scores) decreased from a weighted mean score of 16.0 (SD ± 8.0, n = 12) to 12.0 (SD ± 6.3, n = 12) (t = 2.07, P < .032).
CONCLUSION: Hydroxychloroquine was a suitable option and effective in reducing symptoms and disease severity in patients with recalcitrant OLP who do not adequately respond to standard therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:137 |
|---|---|
| Enthalten in: |
Oral surgery, oral medicine, oral pathology and oral radiology - 137(2024), 4 vom: 15. Apr., Seite 355-361 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chirravur, Prazwala [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 08.04.2024 Date Revised 08.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.oooo.2023.12.007 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367690853 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367690853 | ||
| 003 | DE-627 | ||
| 005 | 20240408232300.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240127s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.oooo.2023.12.007 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1369.xml |
| 035 | |a (DE-627)NLM367690853 | ||
| 035 | |a (NLM)38278674 | ||
| 035 | |a (PII)S2212-4403(23)00764-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chirravur, Prazwala |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hydroxychloroquine for the management of recalcitrant oral lichen planus |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2024 | ||
| 500 | |a Date Revised 08.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a OBJECTIVE: The objective of this study is to describe the efficacy of hydroxychloroquine (HCQ) in patients with oral lichen planus (OLP) refractory to conventional therapy | ||
| 520 | |a STUDY DESIGN: In this single-center retrospective study, patients were prescribed HCQ 200 mg twice daily. Pain, reticulation, erythema, and ulceration scores were recorded. Two-sample and paired t tests were used to evaluate mean and paired pain scores and paired t test to determine substantial differences in paired REU scores, at HCQ initiation visit and final follow-up at 12 to 24 months | ||
| 520 | |a RESULTS: Thirty-six patients (69.4% female) with a median age of 70 ± 12.0 (range 48-99) were initiated on HCQ. Only 30 patients were evaluable because pruritus developed in 5 patients (13.9%) and gastrointestinal symptoms in 1 (2.8%). The mean follow-up was 23.2 months (range 1-74). In 19 patients, there was a significant decline in the worst pain score from a mean of 3.9 (SD± 2.8, n = 19) to 1.9 (SD ± 2.4, n = 19) (t = 2.837, P < .006). Paired reticulation, erythema, and ulceration (REU scores) decreased from a weighted mean score of 16.0 (SD ± 8.0, n = 12) to 12.0 (SD ± 6.3, n = 12) (t = 2.07, P < .032) | ||
| 520 | |a CONCLUSION: Hydroxychloroquine was a suitable option and effective in reducing symptoms and disease severity in patients with recalcitrant OLP who do not adequately respond to standard therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Hydroxychloroquine |2 NLM | |
| 650 | 7 | |a 4QWG6N8QKH |2 NLM | |
| 700 | 1 | |a Sroussi, Herve |e verfasserin |4 aut | |
| 700 | 1 | |a Treister, Nathaniel |e verfasserin |4 aut | |
| 700 | 1 | |a Al Hadlaq, Malak |e verfasserin |4 aut | |
| 700 | 1 | |a Whiting, Brent |e verfasserin |4 aut | |
| 700 | 1 | |a Santoianni, James A |e verfasserin |4 aut | |
| 700 | 1 | |a Woo, Sook Bin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oral surgery, oral medicine, oral pathology and oral radiology |d 2012 |g 137(2024), 4 vom: 15. Apr., Seite 355-361 |w (DE-627)NLM218363591 |x 2212-4411 |7 nnns |
| 773 | 1 | 8 | |g volume:137 |g year:2024 |g number:4 |g day:15 |g month:04 |g pages:355-361 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.oooo.2023.12.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 137 |j 2024 |e 4 |b 15 |c 04 |h 355-361 | ||